Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage and Mobilization Therapy for Refractory or Early Relapsing Patients with Aggressive Non-Hodgkin's Lymphoma

References

• Fisher, RI., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", New England Journal of Medicine, 328, 1002–1006.
   Google Scholar
• Couderc, B., Dujols, J.P., Mokhtari, F., Norkowslci, J.L., Slawinski, J.C., and Schlaifer, D. (2000) "The management of adult aggressive non-Hodgkin's lymphomas", Critical Review Oncology Hematology, 35, 33–48.
   Google Scholar
• Longo, D.L., Duffey, P.L., Young, R.C., Hubbard, S.M., Ihde, D.C., Glatstein, E., et al. (1992) "Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure", Journal of Clinical Oncology, 10, 210–218.
   Google Scholar
• Salles, G., Shipp, M.A. and Coiffier, B. (1994) "Chemotherapy of non-Hodgkin's aggressive lymphomas", Seminars in Hematology, 31, 46–69.
   Google Scholar
• Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., et al. (1995) "Autologous bone marrow transplanta-tion as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", New England Journal of Medicine, 333, 1540— 1545.
   Google Scholar
• Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., et al. (1993) "High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma", Journal of Clinical Oncology, 11, 1846 — 1851.
   Google Scholar
• Lin, T.S. and Copelan, E.A. (2003) "Autologous stem cell transplantation for non-Hodgkin's lymphoma", Current Hemato-lology Reports, 2, 310–315.
   Google Scholar
• Gutierrez, M., Chabner, B.A., Pearson, D., Steinberg, S.M., Jaffe, ES., Cheson, B.D., et al. (2000) "Role of a Doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH", Journal of Clinical Oncology, 18, 3633–3642.
   Google Scholar
• Aurlien, E., Holte, H., Pharo, A., Kvaloy, S., Jakobsen, E., Smeland, E.B., et al. (1998) "Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma", Bone Marrow Transplantation, 21, 873— 878.
   Google Scholar
• Moskowitz, C.H., Bertino, J.R., Glassman, J.R., Hedrick, E.E., Hunte, S., Coady-Lyons, N., et al. (1999) "Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma", Journal of Clinical Oncology, 17, 3776–3785.
   Google Scholar
• Rodriguez, M.A., Cabanillas, F.C., Hagemeister, F.B., McLaugh-lin, P., Romaguera, J.E., Swan, F., et al. (1995) "A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas", Annals of Oncology, 6, 609–611.
   Google Scholar
• Hagemeister, F.B., Tannir, N., McLaughlin, P., Salvador, P., Riggs, S., Velasquez, W.S., et al. (1987) "MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease", Journal of Clinical Oncology, 5, 556— 561.
   Google Scholar
• Cabanillas, F. (1989) "Experience with ifosfamide combinations in malignant lymphomas", Seminars in Oncology, 16, 78–81.
   Google Scholar
• Kingreen, D., Beyer, J., Kleiner, S., Reif, S., Huhn, D. and Siegert, W. (2001) "ICE-an efficient drug combination for stem cell mobilization and high dose treatment of malignant lymphoma", European Journal of Haematology, 66\(Suppl 64), 46— 50.
   Google Scholar
• Zinzani, P.L., Tani, M., Molinari, XL., Stefani, V., Zuffa, E., Alinari, L., et al. (2002) "Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients", Haematologica, 87, 816–821.
   Google Scholar
• Harris, N.L., Jaffe, ES., Stein, H., Banks, P.M., Chan, J.K., Cleary, ML., et al. (1994) "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group", Blood, 84, 1361–1392.
   Google Scholar
• Anonymous (1993) "A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lympho-ma Prognostic Factors Project", New England Journal of Medicine, 329, 987–994.
   Google Scholar
• Cheson, B.D., Horning, Si., Coiffier, B., Shipp, MA., Fisher, RI., Connors, J.M., et al. (1999) . "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group", Journal of Clinical Oncology, 17, 1244 — 1251.
   Google Scholar
• Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. and Goldstone, A.H. (1995) "BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma", Journal of Clinical Oncol-ogy, 13, 588–595.
   Google Scholar
• Kaplan, E.L. and Meier, P. (1958) "Non-parametric estimation from incomplete observations", Journal of American Statistical Association, 53, 457 — 481.
   Google Scholar
• Velasquez, W.S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., et al. (1988) "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)", Blood, 71, 117 — 122.
   Google Scholar
• Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguez, M.A., et al. (1994) "ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study", Journal of Clinical Oncology, 12, 1169 — 1176.
   Google Scholar
• Proctor, Si., Taylor, P.R., Angus, B., Wood, K., Lennard, AL., Lucraft, H., et al. (2001) "High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/ refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy", European Journal of Haematology, (Suppl 64), 28–32.
   Google Scholar
• Joyce, R.M., Kraser, C.N., Tetrealt, J.C., Giallombardo, N., McDermott, D., Levine, J., etal. (2001) "Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant", European Journal of Hae-matology, (Suppl 64), 56–62.
   Google Scholar
• Kewalramani, T., Zelenetz, A. and Bertino, J. (2001) "Rituximab significantly increases the complete rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)", Blood, 98\(Suppl 1), a1459 [abstract].
   Google Scholar
• Joyce, R.M., Regan, M., Ottaway, J., Umiel, T., Tetreault, J.C., Levine, J., etal. (2003) "A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and auto-logous stem cell transplantation (HDC-ASCT)", Annals of Oncol-ogy, 14\(Suppl 1), 21–27.
   Google Scholar